Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO | 630.2k | -- | 1957 |
| Mr. Richard Clavano Narido | Treasurer | 255.01k | -- | 1978 |
| Mr. Michael S. Abrams | Chief Financial Officer | -- | -- | 1970 |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 240k | -- | 1962 |
| Suzanne Messere | Investor Relations | -- | -- | -- |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist | -- | -- | 1947 |
| Mr. Matthew Patrick Duffy | Chief Business Officer & Co-CEO of Hope Therapeutics | -- | -- | 1963 |
NRx Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Corporate Governance
Upcoming Events
May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC
NRx Pharmaceuticals, Inc. Earnings Date